EMA issues positive opinion, recommends full approval of IMBRUVICA(R) (ibrutinib)
Pharmacyclics announced the Committee for Medicinal Products for Human Use of the EMA issued a positive opinion recommending a change to the terms of the marketing authorization for IMBRUVICA® (ibrutinib) in the EU to indicate treatment of adult patients with Waldenström's macroglobulinemia. May 22, 2015